Table 1. Comparison of Juvenile Idiopathic Arthritis-associated Uveitis (JIA-U) and Other Types of Childhood Uveitis.
| Characteristics N = 94 unless otherwise specified N (%) unless otherwise specified |
Overall N=94 |
JIA- associated uveitis N=52 (55.3%) |
Other types of uveitis N=42 (44.7%) |
p-value |
|---|---|---|---|---|
| Demographics | ||||
| Age at most recent visit, Median (25th – 75th) |
11.8 (8.5 – 14.9) |
13.3 (8.4 – 14.6) |
13.3 (9.2 – 15.0) |
0.225 |
| Gender, female | 66 (70.2%) | 40 (76.9%) | 26 (61.9%) | 0.173 |
| Race | ||||
| White | 57 (60.6%) | 38 (73.1%) | 19 (45.2%) | 0.003b |
| African American | 28 (29.8%) | 8 (15.4%) | 20 (47.6%) | |
| Other | 9 (9.6%) | 6 (11.5%) | 3 (7.1%) | |
| Hispanic | 13 (13.8%) | 10 (19.2%) | 3 (7.1%) | 0.184 |
| Insurance | ||||
| Private | 54 (57.5%) | 31 (59.6%) | 23 (54.8%) | 0.863 |
| Medicaid | 37 (39.4%) | 19 (36.5%) | 18 (42.9%) | |
| None | 3 (3.2%) | 2 (3.9%) | 1 (2.4%) | |
| Disease Characteristics | ||||
| Age at uveitis diagnosis (years), Median (25th – 75th) |
6.3 (4.0 – 10.6) |
4.8 (3.5 – 10.4) |
8.7 (5.3 – 10.7) |
0.006 b |
| Location of Disease a (N = 88) | ||||
| Anterior | 65 (73.9%) | 38 (80.9%) | 27 (65.9%) | 0.110 |
| Intermediate | 5 (5.7%) | 0 (0.0%) | 5 (12.2%) | 0.014 b |
| Posterior/Panuveitis | 4 (4.6%) | 0 (0.0%) | 4 (9.8%) | 0.029 b |
| Unknown | 14 (15.9%) | 9 (18.0%) | 5 (12.2%) | 0.373 |
| Bilateral Disease a (N = 89) | 62 (69.7%) | 34 (72.3%) | 28 (66.7%) | 0.562 |
| Worst Ocular Exam a (N=85) | ||||
| Slit lamp exam (cells), | ||||
| 0 & 0.5+ | 19 (22.4%) | 11 (23.9%) | 8 (20.5%) | 0.797 |
| 1+ and worse | 66 (77.6%) | 35 (76.1%) | 31 (79.5%) | |
| Intraocular Pressure Median (25th – 75th) |
20.0 (17.0 – 26.0) |
19.0 (17.0 – 25.0) |
21.0 (17.0 – 28.0) |
0.282 |
| Visual acuity 20/50 or worse |
49 (57.7%) | 21 (44.7%) | 28 (73.7%) | 0.009 b |
| Visual acuity 20/200 or worse |
27 (31.8%) | 9 (19.2%) | 18 (47.4%) | 0.009 b |
| Type of Complications | ||||
| Cataracts | 38 (40.4%) | 16 (30.8%) | 22 (52.4%) | 0.038 b |
| Glaucoma/ocular hypertension | 16 (17.0%) | 9 (17.3%) | 7 (16.7%) | 1.000 |
| Synechiae | 41 (43.6%) | 16 (30.8%) | 25 (59.5%) | 0.007 b |
| Band Keratopathy | 28 (29.8%) | 13 (25.0%) | 15 (35.7%) | 0.364 |
| Cystoid Macular Edema | 22 (23.4%) | 8 (15.4%) | 14 (33.3%) | 0.052 |
| Initial Ocular Exam a | ||||
| ≥1+ cells at first exam, (N=46) | 29 (63.0%) | 16 (61.5%) | 13 (65.0%) | 1.000 |
| Intraocular pressure > 21, (N=25) |
2 (8.0%) | 1 (7.7%) | 1 (8.3%) | 1.000 |
| LogMAR Visual acuity, (N=42) Median (25th – 75th) |
0.18 (0.00 – 0.40) |
0.18 (0.00 – 0.30) |
0.18 (0.10 – 0.48) |
0.622 |
| Labs a | ||||
| ANAc positive (N=92) | 37 (40.2%) | 28 (54.9%) | 9 (22.0%) | 0.003 b |
| Earliest ESRd (N=89) Median (25th – 75th) |
11.0 (6.0 – 29.0) |
22.0 (8.0 – 38.0) |
9.0 (3.0 – 14.0) |
<0.001b |
| HLAe-B27 positive (N=62) | 16 (25.8%) | 6 (18.8%) | 10 (33.3%) | 0.250 |
| Medication Use a (N = 93) | ||||
| Methotrexate Oral | 57 (61.3%) | 36 (70.6%) | 21 (50.0%) | 0.055 |
| Methotrexate Subcutaneous | 65 (69.9%) | 38 (74.5%) | 27 (64.3%) | 0.365 |
| Infliximab | 27 (29.0%) | 17 (33.3%) | 10 (23.8%) | 0.364 |
| Adalimumab | 17 (18.3%) | 12 (23.5%) | 5 (11.9%) | 0.184 |
a
Indicates missing data;
b
p = <0.05; Chi-square tests, two sample t-tests, non-parametric test (Mann Whitney-U or Kolmogorov-Smirnov test).
c
ANA = Antinuclear antibody.
d
ESR = Erythrocyte Sedimentation Rate.
e
HLA = Human Leukocyte Antigen.